BC Partners is considering a sale of German pharmaceutical contract manufacturer Aenova, according to people familiar with the matter.
The private equity firm plans to seek a valuation of more than 1.5 billion euros ($1.8 billion) for the business, one of the people said. BC Partners is working with Rothschild & Co. to gauge interest in Aenova, which could draw interest from buyout firms and other strategic bidders, the people said.
Deliberations are ongoing and there’s no certainty they’ll lead to a sale, according to the people, who asked not to be identified discussing confidential information. Representatives for BC Partners and Rothschild declined to comment.
Source: Bloomberg Quint
By Dinesh Nair and Manuel Baigorri
